Hsbc Holdings PLC Has $48.20 Million Stock Holdings in Tenet Healthcare Corporation $THC

Hsbc Holdings PLC reduced its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 2.4% during the first quarter, Holdings Channel reports. The institutional investor owned 260,114 shares of the company’s stock after selling 6,286 shares during the period. Hsbc Holdings PLC’s holdings in Tenet Healthcare were worth $48,201,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its position in shares of Tenet Healthcare by 1.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,490,350 shares of the company’s stock worth $1,488,484,000 after purchasing an additional 119,809 shares during the period. Boston Partners grew its position in Tenet Healthcare by 15.7% in the 4th quarter. Boston Partners now owns 3,642,136 shares of the company’s stock valued at $723,804,000 after purchasing an additional 494,581 shares during the period. AQR Capital Management LLC increased its stake in Tenet Healthcare by 20.3% during the 4th quarter. AQR Capital Management LLC now owns 2,256,539 shares of the company’s stock valued at $448,419,000 after purchasing an additional 380,116 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Tenet Healthcare by 8.0% in the second quarter. Ameriprise Financial Inc. now owns 2,119,423 shares of the company’s stock valued at $373,020,000 after buying an additional 157,109 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Tenet Healthcare during the fourth quarter valued at about $248,494,000. Institutional investors and hedge funds own 95.44% of the company’s stock.

Insiders Place Their Bets

In other news, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the sale, the director directly owned 24,805 shares of the company’s stock, valued at $4,399,166.75. This trade represents a 10.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the sale, the director owned 16,804 shares in the company, valued at $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.97% of the stock is owned by corporate insiders.

Tenet Healthcare Trading Down 0.2%

NYSE:THC opened at $194.43 on Tuesday. Tenet Healthcare Corporation has a 52 week low of $146.60 and a 52 week high of $247.21. The firm has a 50-day moving average price of $184.41 and a two-hundred day moving average price of $197.41. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36. The firm has a market cap of $16.75 billion, a price-to-earnings ratio of 10.11, a price-to-earnings-growth ratio of 1.61 and a beta of 1.27.

Tenet Healthcare (NYSE:THC) last announced its earnings results on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, topping analysts’ consensus estimates of $4.21 by $0.61. The firm had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. On average, equities analysts expect that Tenet Healthcare Corporation will post 17.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on THC shares. Stephens lowered their target price on shares of Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Wall Street Zen lowered Tenet Healthcare from a “buy” rating to a “hold” rating in a report on Saturday. KeyCorp lowered their price objective on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Weiss Ratings cut Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 2nd. Finally, Morgan Stanley set a $254.00 price target on Tenet Healthcare in a research report on Friday, May 1st. Eighteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Tenet Healthcare currently has an average rating of “Moderate Buy” and an average price target of $244.84.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.